Wealth Enhancement Advisory Services LLC Has $42,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK)

Wealth Enhancement Advisory Services LLC lifted its holdings in OPKO Health, Inc. (NASDAQ:OPK) by 75.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 28,908 shares of the biotechnology company’s stock after purchasing an additional 12,417 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in OPKO Health were worth $42,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of OPKO Health by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 186,783 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 8,064 shares during the period. Two Sigma Advisers LP grew its position in shares of OPKO Health by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 381,197 shares of the biotechnology company’s stock valued at $560,000 after purchasing an additional 8,396 shares during the period. Comerica Bank grew its position in shares of OPKO Health by 18.2% in the 4th quarter. Comerica Bank now owns 106,369 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 16,369 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of OPKO Health by 4.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 455,521 shares of the biotechnology company’s stock valued at $670,000 after purchasing an additional 18,571 shares during the period. Finally, Mercer Global Advisors Inc. ADV grew its position in shares of OPKO Health by 105.6% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 43,167 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 22,167 shares during the period. 64.63% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at OPKO Health

In related news, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were bought at an average price of $1.65 per share, for a total transaction of $165,000.00. Following the purchase, the chief executive officer now directly owns 213,751,448 shares in the company, valued at approximately $352,689,889.20. This trade represents a 0.05% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have purchased a total of 500,000 shares of company stock worth $775,000 in the last 90 days. Corporate insiders own 49.69% of the company’s stock.

OPKO Health Stock Performance

NASDAQ:OPK opened at $1.29 on Thursday. OPKO Health, Inc. has a twelve month low of $1.19 and a twelve month high of $2.04. The company has a quick ratio of 2.28, a current ratio of 2.49 and a debt-to-equity ratio of 0.25. The business has a 50 day moving average price of $1.35 and a two-hundred day moving average price of $1.52. The company has a market cap of $1.02 billion, a P/E ratio of -18.43 and a beta of 1.39.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.03). OPKO Health had a negative return on equity of 2.85% and a negative net margin of 5.66%. The company had revenue of $149.90 million for the quarter, compared to the consensus estimate of $163.13 million. During the same quarter in the prior year, the company earned ($0.12) EPS. The company’s revenue for the quarter was down 13.7% on a year-over-year basis. As a group, analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of OPKO Health in a research report on Monday, April 7th. JPMorgan Chase & Co. assumed coverage on OPKO Health in a research report on Friday, April 25th. They set a “neutral” rating for the company. Barrington Research reaffirmed an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Thursday, May 1st. Finally, Wall Street Zen downgraded OPKO Health from a “hold” rating to a “sell” rating in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $2.75.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.